Chargement en cours...
Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer
AIM: Therapeutic efficacy of anticancer nanomedicine is compromised by tumor stromal barriers. The present study deals with the development of docetaxel loaded PEGylated liposomes (DTXPL) and to investigate the effect of tumor stroma disrupting agent, telmisartan, on anticancer efficacy of DTXPL. ME...
Enregistré dans:
| Publié dans: | Nanomedicine (Lond) |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Future Medicine Ltd
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4910941/ https://ncbi.nlm.nih.gov/pubmed/27171485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/nnm.16.37 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|